Robert J. Pelham

1. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies
   2026/02/07 by Tadashi Manabe, Hannah C. Bergo, Qingtian Li +21 · 1 voice
   Biochemistry, Genetics and Molecular Biology · Medicine · #Lung Cancer Treatments and Mutations #Melanoma and MAPK Pathways #NF-κB Signaling Pathways